Triumeq/Triumeq PD (abacavir/dolutegravir/lamivudine) – Expanded indication
June 15, 2023, - The FDA approved ViiV Healthcare’s Triumeq and Triumeq PD (abacavir/dolutegravir/lamivudine), for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.
Top